Thymalfasin to Boost COVID-19 Vaccine Response in Older Adults
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This trial tests whether a drug called thymalfasin (thymosin alpha 1) can help older adults (65+) get a stronger immune response from their COVID-19 booster shot. It may be especially helpful for those whose immune systems have weakened with age.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 65 or older.
- Scheduled to receive a COVID-19 mRNA booster.
- Not severely immunocompromised (e.g., no active cancer treatment, no organ transplant, no HIV with low CD4).
- No history of heart inflammation (myocarditis) or severe allergic reaction to vaccines.
- No significant kidney or liver disease.
- No recent COVID-19 infection or vaccination (within 6 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called thymalfasin, which may help the immune system recover in adults with sepsis (a severe infection that causes organ damage). It aims to see if this treatment can improve immune function and possibly outcomes.
This study tests an updated mRNA COVID-19 vaccine to see how well it boosts immunity and how safe it is. It may help protect you from severe COVID-19 if you are older or have certain health conditions.
This study looks at how well a COVID-19 booster works in adults who need long-term medicines that lower immune response. It aims to see whether immunosuppressed people benefit from booster vaccination safely.
This trial tests an updated COVID-19 booster vaccine designed to improve protection for people who are older or have health conditions that increase their risk of severe COVID-19. If you qualify, you would receive one dose of the study vaccine and be monitored for safety and immune response.
This study tests whether giving a low dose of the medicine sirolimus (rapamycin) before the flu or RSV vaccine improves the body's immune response in older adults on dialysis. It may help make vaccines work better for you.
This trial studies how well your immune system responds to a vaccine in people who are younger adults or, especially, older adults and those with frailty. Your participation may help researchers understand why vaccine responses can differ with age.
Hear when a new Vaccine Response trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.